Swedberg K., Cleland J.,
Dargie
H. et al. Guidelines for the diagnosis and
treatment of chronic heart failure: executive summary (update 2005). The Taskforce for
the Diagnosis and Treatment of Chronic Heart Failure of the European Society of
Cardiology . Eur Heart
J2005;26:1115-40.
2.
Pfeffer MA, McMurray JJ,
Velazquez
EJ et al. Valsartan, captopril, or both in
myocardial infarction complicated by heart failure, left ventricular dysfunction, or
both. N Engl J
Med2003;349:1893-906.
3.
Granger CB, McMurray JJV,
Yusuf
S. et al. Effects of candesartan in patients
with chronic heart failure and reduced left-ventricular systolic function intolerant to
angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.
Lancet2003;362:772-6.
4.
McMurray JJV , Östergren J.,
Swedberg
K. et al. Effects of candesartan in patients
with chronic heart failure and reduced left-ventricular systolic function taking
angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.
Lancet2003;362:
767-71.
5.
Yusuf S., Pfeffer MA,
Swedberg
K. et al. Effects of candesartan in patients
with chronic heart failure and preserved left-ventricular ejection fraction: the
CHARM-Preserved Trial .
Lancet2003;362:777-81.
